title: [Unilatelaral iris plateau syndrome after the use of ecstasy].
abstract: BACKGROUND
  Courmon street name for 3,4-Methylenedioxymethamphetamine (MDMA) is ecstasy. This widely abused "recreational" drug causes both an increased release of monoamine neurotransmitters, including serotonine and dopamine, and an increased reuptake inhibition of serotonin. As a consequence, mydriasis and increased intraocular pressure (IOP) in predisposed patients occur. We present herein a rare case of acute increased IOP after use of ecstasy.
  
  
  METHODS
  A female patient, aged 38 years, visited doctor complaing of a decreased vision acuity and severe pain in the left eye and in the left part of the head. The initial treatment was urgent antiglaucomatous therapy followed by withdrawal of subjective problems of the patient and improvement of objective finding. History taking procedure revaled that just before the onset of the pain the patient had used ecstasy and had had similar "experience" 6 years ago after cocaine snorting. She had not been to a doctor although she had experienced sporadic migrenous pain. Previous medical records excavation of revealed optic disk (cup-to-dise C/D=06), Bjerum arcuate scotoma and iris plateau with narrow chamber angle (Scheie II-III) so the diagnosis was a rare unilateral iris plateau syndrome of the left eye. Although the patient was given some pieces of information about the dangerous and possible deadly consequences of psychoactive substanace abuse, she has not continue the treatment.
  
  
  CONCLUSIONS
  Ecstasy abuse might cause a complete loss of vision, thus medicametous and surgical treatment are abligatory.
authors: Klinicki centar, Klinika za ocne bolesti, Nis, Srbija. pedjaj@bankerinter.net
authors: Predrag
authors: P
authors: Jovanović
authors: Paraskeva
authors: P
authors: Hentova-Senćanić
authors: Lepsa
authors: L
authors: Zorić
authors: Maja
authors: M
authors: Petrović
authors: Marija Trenkić
authors: MT
authors: Bozinović
mesh_terms: D000328:Adult; D005260:Female; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects*; D009798:Ocular Hypertension / Q000139:chemically induced; D019966:Substance-Related Disorders / Q000150:complications*
chemical_list: D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine